Acute Hemodynamic Effects of Conivaptan, a Dual V 1A and V 2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure

Background Arginine vasopressin may contribute to abnormalities in hemodynamics and fluid balance in heart failure through its actions on V 1A (vascular and myocardial effects) and V 2 receptors (renal effects). Inhibiting the action of vasopressin may be beneficial in patients with heart failure. M...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2001-11, Vol.104 (20), p.2417-2423
Main Authors: Udelson, James E., Smith, William B., Hendrix, Grady H., Painchaud, Christopher A., Ghazzi, Maha, Thomas, Ignatius, Ghali, Jalal K., Selaru, Paulina, Chanoine, Francoise, Pressler, Milton L., Konstam, Marvin A.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Arginine vasopressin may contribute to abnormalities in hemodynamics and fluid balance in heart failure through its actions on V 1A (vascular and myocardial effects) and V 2 receptors (renal effects). Inhibiting the action of vasopressin may be beneficial in patients with heart failure. Methods and Results A total of 142 patients with symptomatic heart failure (New York Heart Association class III and IV) were randomized to double-blind, short-term treatment with conivaptan, a dual V 1a /V 2 vasopressin receptor antagonist, at a single intravenous dose (10, 20, or 40 mg) or placebo. Compared with placebo, conivaptan at 20 and 40 mg significantly reduced pulmonary capillary wedge pressure (−2.6±0.7, −5.4±0.7, and −4.6±0.7 mm Hg for placebo and 20 and 40 mg groups, respectively; P
ISSN:0009-7322
1524-4539
DOI:10.1161/hc4501.099313